{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:38:04Z","timestamp":1780097884890,"version":"3.54.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR241"],"award-info":[{"award-number":["TRR241"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR417"],"award-info":[{"award-number":["TRR417"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1181"],"award-info":[{"award-number":["SFB1181"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.smim.2025.102013","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:25:32Z","timestamp":1765913132000},"page":"102013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["New insights into Th9 cells in inflammatory bowel diseases"],"prefix":"10.1016","volume":"81","author":[{"given":"Markus F.","family":"Neurath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2025.102013_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0091-6749(82)90057-4","article-title":"The regulation of mucosal immune system","volume":"70","author":"Strober","year":"1982","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41575-019-0261-4","article-title":"Epithelial Toll-like receptors and their role in gut homeostasis and disease","volume":"17","author":"Burgueno","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102013_bib3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.102013_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: a pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102013_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0002-9610(99)80121-4","article-title":"Cytokines in Crohn's colitis","volume":"169","author":"Sher","year":"1995","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.smim.2025.102013_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41385-022-00488-w","article-title":"IL-36 cytokines imprint a colitogenic phenotype on CD4(+) T helper cells","volume":"15","author":"Leon","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/ibd.21905","article-title":"Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases","volume":"18","author":"Verdier","year":"2012","journal-title":"Inflamm. bowel Dis."},{"key":"10.1016\/j.smim.2025.102013_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2015-310187","article-title":"Development and validation of the Nancy histological index for UC","volume":"66","author":"Marchal-Bressenot","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib10","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/apt.15190","article-title":"One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing","volume":"49","author":"Castiglione","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.smim.2025.102013_bib11","first-page":"1928","article-title":"Transmural healing evaluated by bowel sonography in patients with Crohn's disease on maintenance treatment with biologics","volume":"19","author":"Castiglione","year":"2013","journal-title":"Inflamm. bowel Dis."},{"key":"10.1016\/j.smim.2025.102013_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S2468-1253(21)00096-0","article-title":"Transmural healing as a therapeutic goal in Crohn's disease: a systematic review","volume":"6","author":"Geyl","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102013_bib13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.smim.2025.102013_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ibd.21417","article-title":"Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts","volume":"17","author":"Peyrin-Biroulet","year":"2011","journal-title":"Inflamm. bowel Dis."},{"key":"10.1016\/j.smim.2025.102013_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2016.09.047","article-title":"Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases","volume":"152","author":"Rieder","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102013_bib16","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn's disease complicated by strictures: a systematic review","volume":"62","author":"Rieder","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib17","first-page":"1","article-title":"ECCO-ESCP Consensus on Surgery for Crohn's Disease","volume":"12","author":"Bemelman","year":"2018","journal-title":"J. Crohn's. Colitis"},{"key":"10.1016\/j.smim.2025.102013_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000495127","article-title":"Impact of Modern Drug Therapy on Surgery: Crohn's Disease","volume":"34","author":"Kienle","year":"2018","journal-title":"Visc. Med."},{"key":"10.1016\/j.smim.2025.102013_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcmgh.2014.11.006","article-title":"Mechanisms of Immune Signaling in Colitis-Associated Cancer","volume":"1","author":"Waldner","year":"2015","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102013_bib20","article-title":"Risk and Location of Cancer in Patients With Preoperative Colitis-Associated Dysplasia Undergoing Proctocolectomy","author":"Kiran","year":"2013","journal-title":"Ann. Surg."},{"key":"10.1016\/j.smim.2025.102013_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrgastro.2017.136","article-title":"Environmental triggers in IBD: a review of progress and evidence","volume":"15","author":"Ananthakrishnan","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102013_bib22","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102013_bib23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00439-023-02521-9","article-title":"The genetics of non-monogenic IBD","volume":"142","author":"Jans","year":"2023","journal-title":"Hum. Genet"},{"issue":"1","key":"10.1016\/j.smim.2025.102013_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000341130","article-title":"The genetics universe of Crohn's disease and ulcerative colitis","volume":"30","author":"Parkes","year":"2012","journal-title":"Dig. Dis."},{"key":"10.1016\/j.smim.2025.102013_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ecco-jcc\/jjac124","article-title":"NOD2 in Crohn's Disease-Unfinished Business","volume":"17","author":"Ashton","year":"2023","journal-title":"J. Crohn's. Colitis"},{"key":"10.1016\/j.smim.2025.102013_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.102013_bib27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nature07416","article-title":"A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells","volume":"456","author":"Cadwell","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.smim.2025.102013_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ng1954","article-title":"A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1","volume":"39","author":"Hampe","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.smim.2025.102013_bib29","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1073\/pnas.1407001111","article-title":"Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense","volume":"111","author":"Lassen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.smim.2025.102013_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/MCG.0b013e318168bdf0","article-title":"Genetic variants in IL-23R and ATG16L1 independently predispose to increased susceptibility to Crohn's disease in a Canadian population","volume":"43","author":"Newman","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.smim.2025.102013_bib31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ibd.20126","article-title":"IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease","volume":"13","author":"Dubinsky","year":"2007","journal-title":"Inflamm. bowel Dis."},{"key":"10.1016\/j.smim.2025.102013_bib32","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.2174\/138161210794079164","article-title":"Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases","volume":"16","author":"De Nitto","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.smim.2025.102013_bib33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ibd.21677","article-title":"Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease","volume":"18","author":"Hundorfean","year":"2012","journal-title":"Inflamm. bowel Dis."},{"key":"10.1016\/j.smim.2025.102013_bib34","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/mi.2012.124","article-title":"TL1A\/TNFSF15 directly induces proinflammatory cytokines, including TNFalpha, from CD3+CD161+ T cells to exacerbate gut inflammation","volume":"6","author":"Jin","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MCG.0b013e3182688e73","article-title":"Mucin function in inflammatory bowel disease: an update","volume":"47","author":"Boltin","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.smim.2025.102013_bib36","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1155\/2013\/102859","article-title":"Environment and the inflammatory bowel diseases","volume":"27","author":"Frolkis","year":"2013","journal-title":"Can. J. Gastroenterol. = J. Can. De. Gastroenterol."},{"key":"10.1016\/j.smim.2025.102013_bib37","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13409","article-title":"Human microbiome and metabolic health: An overview of systematic reviews","volume":"23","author":"Michels","year":"2022","journal-title":"Obes. Rev."},{"key":"10.1016\/j.smim.2025.102013_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000470892","article-title":"The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond","volume":"33","author":"Chiriac","year":"2017","journal-title":"Visc. Med."},{"key":"10.1016\/j.smim.2025.102013_bib40","article-title":"Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERIca Trial","author":"Rath","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102013_bib41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MCG.0b013e3181fbdb8a","article-title":"Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease","volume":"45","author":"Liu","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.smim.2025.102013_bib42","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/gutjnl-2011-300695","article-title":"Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease","volume":"61","author":"Kiesslich","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","author":"Neurath","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054562","article-title":"Distinct profiles of effector cytokines mark the different phases of Crohn's disease","volume":"8","author":"Zorzi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2025.102013_bib45","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156652412800620066","article-title":"Th17-related cytokines in inflammatory bowel diseases: friends or foes?","volume":"12","author":"Monteleone","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.smim.2025.102013_bib46","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1084\/jem.20011956","article-title":"The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease","volume":"195","author":"Neurath","year":"2002","journal-title":"J. Exp. Med"},{"issue":"1","key":"10.1016\/j.smim.2025.102013_bib47","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/mi.2008.40","article-title":"The role of IL-13 and NK T cells in experimental and human ulcerative colitis","volume":"1","author":"Fuss","year":"2008","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1741-7015-9-122","article-title":"Th17-related cytokines: new players in the control of chronic intestinal inflammation","volume":"9","author":"Monteleone","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.smim.2025.102013_bib49","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn's disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm0107-26","article-title":"IL-23: a master regulator in Crohn disease","volume":"13","author":"Neurath","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2025.102013_bib51","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1053\/j.gastro.2005.03.043","article-title":"Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease","volume":"128","author":"Maul","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102013_bib52","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4049\/immunohorizons.2200071","article-title":"Intestinal Tr1 Cells Confer Protection against Colitis in the Absence of Foxp3+ Regulatory T Cell-Derived IL-10","volume":"7","author":"Zhou","year":"2023","journal-title":"Immunohorizons"},{"key":"10.1016\/j.smim.2025.102013_bib53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.smim.2006.01.007","article-title":"Tr1 cells: from discovery to their clinical application","volume":"18","author":"Battaglia","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib54","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.102013_bib55","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.102013_bib56","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohn's. Colitis"},{"key":"10.1016\/j.smim.2025.102013_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102013_bib58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","article-title":"Long-term outcome after infliximab for refractory ulcerative colitis","volume":"2","author":"Ferrante","year":"2008","journal-title":"J. Crohn's. Colitis"},{"key":"10.1016\/j.smim.2025.102013_bib59","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102013_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2024-332919","article-title":"Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?","volume":"74","author":"Neurath","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib61","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJMc2508023","article-title":"CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis","volume":"393","author":"Muller","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.102013_bib62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ibd.21038","article-title":"Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study","volume":"16","author":"Reinisch","year":"2010","journal-title":"Inflamm. bowel Dis."},{"key":"10.1016\/j.smim.2025.102013_bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","article-title":"Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"64","author":"Danese","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2014-308337","article-title":"Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study","author":"Reinisch","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib65","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.102013_bib66","article-title":"Adalimumab Induces Deep Remission in Patients With Crohn's Disease","author":"Colombel","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.smim.2025.102013_bib67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102013_bib68","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2025.102013_bib69","first-page":"105","article-title":"Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.smim.2025.102013_bib70","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102013_bib71","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4049\/jimmunol.1102840","article-title":"STAT6-dependent regulation of Th9 development","volume":"188","author":"Goswami","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib72","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.4049\/jimmunol.1003049","article-title":"A brief history of IL-9","volume":"186","author":"Goswami","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib73","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.4049\/jimmunol.1201496","article-title":"Gcn5 is required for PU.1-dependent IL-9 induction in Th9 cells","volume":"189","author":"Goswami","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib74","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1172\/JCI69489","article-title":"Th9 cell development requires a BATF-regulated transcriptional network","volume":"123","author":"Jabeen","year":"2013","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2025.102013_bib75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.coi.2012.02.001","article-title":"The symphony of the ninth: the development and function of Th9 cells","volume":"24","author":"Jabeen","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib76","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/imr.12028","article-title":"Th9 cells: differentiation and disease","volume":"252","author":"Kaplan","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.smim.2025.102013_bib77","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri3824","article-title":"The development and in vivo function of T helper 9 cells","volume":"15","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00281-016-0611-z","article-title":"Th9 cells in immunity and immunopathological diseases","volume":"39","author":"Neurath","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.smim.2025.102013_bib79","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2015.01.021","article-title":"TH9 cells are required for tissue mast cell accumulation during allergic inflammation","volume":"136","author":"Sehra","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib80","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.4049\/jimmunol.2100165","article-title":"STAT5 Represses a STAT3-Independent Th17-like Program during Th9 Cell Differentiation","volume":"207","author":"Canaria","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib81","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.4049\/jimmunol.1501801","article-title":"STAT3 Impairs STAT5 Activation in the Development of IL-9-Secreting T Cells","volume":"196","author":"Olson","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib82","article-title":"Targeting Th9 cells in autoimmune diseases: a narrative review","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123720","article-title":"Th9-derived IL-9 in autoimmune diseases: An update","volume":"375","author":"Chen","year":"2025","journal-title":"Life Sci."},{"key":"10.1016\/j.smim.2025.102013_bib84","article-title":"Regulatory mechanisms of Th9 cell differentiation","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2025.111343","article-title":"A reappraisal of the contribution of Th9 cells and interleukin-9 to the pathogenesis of rheumatoid arthritis","volume":"86","author":"Jafarzadeh","year":"2025","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib86","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ni.2925","article-title":"The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells","volume":"15","author":"Vegran","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib87","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ni.2920","article-title":"TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells","volume":"15","author":"Gerlach","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib88","article-title":"IL-9 and its receptor are predominantly involved in the pathogenesis of UC","author":"Nalleweg","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib89","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0394632015600535","article-title":"Significance of serum Il-9 levels in inflammatory bowel disease","volume":"28","author":"Defendenti","year":"2015","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.smim.2025.102013_bib90","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.bbrc.2015.11.057","article-title":"IL-9 antibody injection suppresses the inflammation in colitis mice","volume":"468","author":"Yuan","year":"2015","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.smim.2025.102013_bib91","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1073\/pnas.0912678107","article-title":"Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1\/Th2 driven enteritis","volume":"107","author":"Pastorelli","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.smim.2025.102013_bib92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.imlet.2009.11.001","article-title":"IL-33 is upregulated in colonocytes of ulcerative colitis","volume":"128","author":"Seidelin","year":"2010","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.smim.2025.102013_bib93","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/08830185.2018.1457659","article-title":"Th9 Cells: Probable players in ulcerative colitis pathogenesis","volume":"37","author":"Shohan","year":"2018","journal-title":"Int Rev. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib94","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/08820139.2018.1486411","article-title":"Intensified Th9 Response is Associated with the Immunopathogenesis of Active Ulcerative Colitis","volume":"47","author":"Shohan","year":"2018","journal-title":"Immunol. Invest"},{"key":"10.1016\/j.smim.2025.102013_bib95","article-title":"Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 Reduces Colitis in Mice","author":"Popp","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.smim.2025.102013_bib96","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/ibd.21476","article-title":"IRF4 regulates IL-17A promoter activity and controls RORgammat-dependent Th17 colitis in vivo","volume":"17","author":"Mudter","year":"2011","journal-title":"Inflamm. bowel Dis."},{"key":"10.1016\/j.smim.2025.102013_bib97","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181521","article-title":"IL-9 promotes the pathogenesis of ulcerative colitis through STAT3\/SOCS3 signaling","volume":"38","author":"Tian","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.smim.2025.102013_bib98","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3389\/fimmu.2018.01139","article-title":"A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease","volume":"9","author":"Vyas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib99","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.advms.2018.03.002","article-title":"Th9 lymphocytes and functions of interleukin 9 with the focus on IBD pathology","volume":"63","author":"Matusiewicz","year":"2018","journal-title":"Adv. Med Sci."},{"key":"10.1016\/j.smim.2025.102013_bib100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00281-016-0603-z","article-title":"Th9 cells in inflammatory bowel diseases","volume":"39","author":"Weigmann","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.smim.2025.102013_bib101","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nprot.2007.41","article-title":"Chemically induced mouse models of intestinal inflammation","volume":"2","author":"Wirtz","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.smim.2025.102013_bib102","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/nprot.2017.044","article-title":"Chemically induced mouse models of acute and chronic intestinal inflammation","volume":"12","author":"Wirtz","year":"2017","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.smim.2025.102013_bib103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/mi.2012.77","article-title":"IL-9-producing invariant NKT cells protect against DSS-induced colitis in an IL-4-dependent manner","volume":"6","author":"Kim","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib104","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41467-019-10889-4","article-title":"Fas signaling-mediated T(H)9 cell differentiation favors bowel inflammation and antitumor functions","volume":"10","author":"Shen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.102013_bib105","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/ni.1677","article-title":"IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells","volume":"9","author":"Dardalhon","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib106","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/eji.201948430","article-title":"IL-9 exerts biological function on antigen-experienced murine T cells and exacerbates colitis induced by adoptive transfer","volume":"50","author":"de Heusch","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib107","doi-asserted-by":"crossref","first-page":"E2940","DOI":"10.1073\/pnas.1708329115","article-title":"CD96 expression determines the inflammatory potential of IL-9-producing Th9 cells","volume":"115","author":"Stanko","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.smim.2025.102013_bib108","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/mi.2017.21","article-title":"IL-36gamma signaling controls the induced regulatory T cell-Th9 cell balance via NFkappaB activation and STAT transcription factors","volume":"10","author":"Harusato","year":"2017","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib109","first-page":"4772","article-title":"VEGF-C mediated enhancement of lymphatic drainage reduces intestinal inflammation by regulating IL-9\/IL-17 balance and improving gut microbiota in experimental chronic colitis","volume":"9","author":"Wang","year":"2017","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.smim.2025.102013_bib110","doi-asserted-by":"crossref","DOI":"10.4161\/21688370.2014.983777","article-title":"IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis","volume":"3","author":"Gerlach","year":"2015","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.smim.2025.102013_bib111","article-title":"TL1A\/DR3 signaling regulates the generation of pathogenic Th9 cells in experimental inflammatory bowel disease","author":"Menghini","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.smim.2025.102013_bib112","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520926011","article-title":"Tumor necrosis factor ligand-related molecule 1A affects the intestinal mucosal barrier function by promoting Th9\/interleukin-9 expression","volume":"48","author":"Zhao","year":"2020","journal-title":"J. Int Med Res"},{"key":"10.1016\/j.smim.2025.102013_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.06.011","article-title":"TL1A modulates the severity of colitis by promoting Th9 differentiation and IL-9 secretion","volume":"231","author":"Wang","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.smim.2025.102013_bib114","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1038\/s41467-018-07581-4","article-title":"Molecular and functional heterogeneity of IL-10-producing CD4(+) T cells","volume":"9","author":"Brockmann","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2025.102013_bib115","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.4049\/jimmunol.177.9.5852","article-title":"Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis","volume":"177","author":"Uhlig","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib116","article-title":"Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study","volume":"13","author":"Toskas","year":"2023","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.smim.2025.102013_bib117","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jleuko\/qiae069","article-title":"The IL-21\/IL-21R signaling axis regulates CD4+ T-cell responsiveness to IL-12 to promote bacterial-induced colitis","volume":"116","author":"Solaymani-Mohammadi","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.smim.2025.102013_bib118","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/eji.200737766","article-title":"IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells","volume":"37","author":"Fantini","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib119","first-page":"1","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1385\/CRIAI:28:3:187","article-title":"Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer","volume":"28","author":"Atreya","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.smim.2025.102013_bib121","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.smim.2025.102013_bib122","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-14-93","article-title":"A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma","volume":"14","author":"Oh","year":"2013","journal-title":"Respir. Res."},{"key":"10.1016\/j.smim.2025.102013_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108191","article-title":"Neobavaisoflavone-mediated T(H)9 cell differentiation ameliorates bowel inflammation","volume":"101","author":"Guo","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.smim.2025.102013_bib124","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial","volume":"10","author":"Danese","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.smim.2025.102013_bib125","first-page":"2324","article-title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.smim.2025.102013_bib126","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.102013_bib127","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/gutjnl-2024-332504","article-title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD","volume":"74","author":"Bamias","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.smim.2025.102013_bib128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10620-024-08792-0","article-title":"Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD","volume":"70","author":"Fansiwala","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.smim.2025.102013_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2025.102577","article-title":"Targeting the unmet needs in IBD: Emerging therapies beyond biologics and small molecules","volume":"85","author":"Fanizzi","year":"2025","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.smim.2025.102013_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17101325","article-title":"Orally Dispersible Swallowed Topical Corticosteroids in Eosinophilic Esophagitis: A Paradigm Shift in the Management of Esophageal Inflammation","volume":"17","author":"Barchi","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.smim.2025.102013_bib131","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/ecco-jcc\/jjac097","article-title":"PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial Cells","volume":"16","author":"Gerlach","year":"2022","journal-title":"J. Crohn's. Colitis"},{"key":"10.1016\/j.smim.2025.102013_bib132","doi-asserted-by":"crossref","DOI":"10.1177\/11795549241301358","article-title":"Th9 and Th17 Cells in Human Ulcerative Colitis-Associated Dysplastic Lesions","volume":"18","author":"Cui","year":"2024","journal-title":"Clin. Med Insights Oncol."},{"key":"10.1016\/j.smim.2025.102013_bib133","article-title":"Lentiviral vector-mediated IL-9 overexpression stimulates cell proliferation by targeting c-myc and cyclin D1 in colitis-associated cancer","author":"Tian","year":"2019","journal-title":"Oncol. Lett. 17 175182"},{"key":"10.1016\/j.smim.2025.102013_bib134","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2004.07.020","article-title":"TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling","volume":"21","author":"Becker","year":"2004","journal-title":"Immunity"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:34:00Z","timestamp":1773912840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532325000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":134,"alternative-id":["S1044532325000855"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.102013","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into Th9 cells in inflammatory bowel diseases","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.102013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102013"}}